Biblio Discovery — Demo Discovery Service

7 hasil untuk "Maria Papathanassiou"

Menampilkan 1–7 · 0,62 detik · RSS

  1. Artikel Jurnal

    Historia Alexandri Magni : astronomy, astrology and tradition

    Maria Papathanassiou

    Dialogues d'Histoire Ancienne, Vol. 25 No. 2 · 1999 · Italia · DOAJ Scopus

    One MS. (Paris. gr. 1711, 11th cen.) of Alexander the Great's Story by Ps.-Callisthenes includes passage giving information on the positions of the Sun, the Moon, and the five planets in the zodiac at the time of Alexander's birth. According to my research this information does not refer to…

  2. Artikel Jurnal Teks lengkap

    DNA Repair Gene Polymorphisms and Susceptibility to Urothelial Carcinoma in a Southeastern European Population

    Maria Samara; Maria Papathanassiou; Lampros Mitrakas dkk.

    Current Oncology, Vol. 28 No. 3 · 2021 · Inggris · DOAJ Scopus

    Single nucleotide polymorphisms (SNPs) in DNA repair genes may predispose to urothelial carcinoma of the bladder (UCB). This study focused on three specific SNPs in a population with high exposure to environmental carcinogens including tobacco and alcohol. A case-control study design was used to…

  3. Artikel Jurnal Teks lengkap

    Hypoxia-Inducible Factor-2-Altered Urothelial Carcinoma: Clinical and Genomic Features

    Panagiotis J. Vlachostergios; Ioannis A. Tamposis; Maria Anagnostou dkk.

    Current Oncology, Vol. 29 No. 11 · 2022 · Inggris · DOAJ Scopus

    Background: Hypoxia is recognized as a key feature of cancer growth and is involved in various cellular processes, including proliferation, angiogenesis, and immune surveillance. Besides hypoxia-inducible factor 1-alpha (HIF-1α), which is the main mediator of hypoxia effects and can also be…

  4. Artikel Jurnal

    Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma

    Iraklis C. Mitsogiannis; Maria Mitsogianni; Maria Papathanassiou dkk.

    Journal of Kidney Cancer and VHL, Vol. 9 No. 3 · 2022 · Inggris · DOAJ

    Standard systemic therapy of advanced renal cell carcinoma (RCC) involves targeting angiogenesis, mainly through tyrosine kinase inhibitors (TKI) against the vascular endothelial growth factor receptor (VEGFR) pathway and targeting the immune checkpoints, namely, programmed death-1 (PD-1) or its…

  5. Artikel Jurnal

    Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition [version 2; peer review: 2 approved]

    Maria Samara; Vassilios Tzortzis; Maria Ioannou dkk.

    F1000Research, Vol. 12 · 2024 · Inggris · DOAJ Scopus

    Background The risk of recurrence after nephrectomy for primary clear cell renal cell carcinoma (ccRCC) is estimated in daily practice solely based on clinical criteria. The aim of this study was to assess the prognostic relevance of common somatic mutations with respect to tumor aggressiveness and…

  6. Artikel Jurnal

    Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis

    Maria Papathanassiou; Ioannis Tamposis; Kalliopi K. Exarchou-Kouveli dkk.

    Frontiers in Oncology, Vol. 12 · 2022 · Inggris · DOAJ Scopus

    IntroductionThe use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient’ outcome. However, little is known about the efficacy or lack thereof of immunotherapy after prior use of anti-PD1/PD-L1 or/and anti-CTLA…

  7. Artikel Jurnal Teks lengkap

    Renin-Angiotensin System Single Nucleotide Polymorphisms Are Associated with Bladder Cancer Risk

    Maria Samara; Maria Papathanassiou; Ioanna Farmakioti dkk.

    Current Oncology, Vol. 28 No. 6 · 2021 · Inggris · DOAJ Scopus

    The renin-angiotensin system (RAS), besides being a major regulator of blood pressure, is also involved in tumor angiogenesis. Emerging evidence suggests a correlation between the use of pharmacologic RAS inhibitors and a delay in urothelial bladder cancer (BC) progression. However, it is unknown…